Earnings: Page
-
Boston Scientific continues to win in electrophysiology
Strong sales growth in the company’s electrophysiology unit comes amid a market fight between some of the medtech industry’s largest players.
By Ricky Zipp • Oct. 22, 2025 -
Intuitive Surgical reports strong Q3 as da Vinci procedures climb
Intuitive Surgical’s shares surged nearly 15% early Wednesday after the robot maker’s third-quarter sales and earnings topped analysts’ expectations.
By Susan Kelly • Oct. 22, 2025 -
Abbott CEO: ‘We’re right on time’ to the PFA party
As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.
By Elise Reuter • Oct. 15, 2025 -
Medtech firms splitting into ‘haves’ and ‘have-nots’: EY
The number of medtech funding rounds has declined in recent months, but the value of overall deals has increased, according to a new report from EY.
By Elise Reuter • Sept. 29, 2025 -
Medtronic adds 2 board seats, forms special committees
CEO Geoff Martha told investors that the initiatives were done in partnership with the activist investor firm Elliott Investment Management.
By Ricky Zipp • Aug. 19, 2025 -
Vicarious Surgical delays robot timeline
Days into the job, CEO Stephen From said the company no longer expects to begin a clinical trial for its robotic system by the end of the year.
By Susan Kelly • Aug. 13, 2025 -
Masimo appoints several senior execs, resolves cyber incident
The pulse oximeter maker is now fully operational after a spring cyberattack and increased its 2025 profit forecast, but investors have raised questions about the status of a partnership with Philips.
By Susan Kelly • Aug. 8, 2025 -
Zimmer is latest medtech firm to lower expected tariff hit
CFO Suketu Upadhyay said the company now expects a charge in 2025 of about $40 million, compared with a range of $60 million to $80 million.
By Ricky Zipp • Aug. 7, 2025 -
Stryker lowers expected tariff impact to $175M
The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing strength in procedure demand.
By Elise Reuter • Aug. 1, 2025 -
Dexcom raises sales expectations, discusses G8 plans
Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and over-the-counter devices to drive future growth.
By Elise Reuter • July 31, 2025 -
Earnings & Tariffs
Medtech firms slash expected tariff charges
This earnings season, top medical device companies have dramatically reduced their expectations for tariff impacts in 2025. Check out MedTech Dive’s coverage.
By Ricky Zipp • July 30, 2025 -
Earnings & Tariffs
Siemens Healthineers cuts tariff impact after trade talk breakthrough
The company predicted a full-year impact of 200 million to 250 million euros, down from its previous forecast of up to 300 million euros.
By Nick Paul Taylor • July 30, 2025 -
Quest, Labcorp downplay ‘Big Beautiful Bill’ impact
Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and domestic policy bill, including cuts to Medicaid, will be minimal.
By Susan Kelly • July 29, 2025 -
Earnings & Tariffs
Philips lowers expected tariff hit to 150M to 200M euros
The company previously forecast an up to 300 million euro tariff impact in 2025 before the U.S. struck agreements with China and the European Union.
By Elise Reuter • July 29, 2025 -
Edwards loses longtime TAVR leader Larry Wood
Wood, who helped build Edwards’ TAVR business, will become CEO of Procept BioRobotics. Edwards also raised its sales and earnings outlook for the full year.
By Susan Kelly • July 25, 2025 -
Earnings & Tariffs
Boston Scientific halves expected tariff hit
The company now expects a tariff charge of $100 million this year, down from a $200 million impact forecast on the company’s first-quarter earnings call.
By Ricky Zipp • July 23, 2025 -
Earnings & Tariffs
Intuitive Surgical tempers tariff impact expectations
Executives also addressed Medicaid concerns and competition from third-party suppliers of remanufactured surgical instruments on an earnings call.
By Susan Kelly • July 23, 2025 -
Earnings & Tariffs
Abbott lowers sales forecast on diagnostics decline, US funding cuts
Medical device sales remained a bright spot for the company, however, with more than 20% growth in diabetes devices.
By Elise Reuter • July 17, 2025 -
Earnings & Tariffs
‘We are not rolling over’: J&J electrophysiology unit rebounds amid PFA rivalry
The division returned to growth in the second quarter after declining over the previous three months. Now, can the healthcare giant catch up with its rivals in pulsed field ablation?
By Ricky Zipp • July 16, 2025 -
Trump tariffs
J&J may take a softer tariff hit after US-China pause, CFO says
Joseph Wolk told an investor conference that the company’s tariff estimate is a “moving target” as trade talks continue with China and Europe and Section 232 investigations are ongoing.
By Susan Kelly • June 4, 2025 -
Why Medtronic plans to spin out its diabetes business
While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.
By Elise Reuter • May 22, 2025 -
Trump tariffs
Cost cuts, production shifts: How medtech firms are managing tariffs
Many companies forecast specific tariff charges. Then the White House and China agreed to a 90-day pause in their trade standoff.
By Susan Kelly • May 22, 2025 -
Medtronic plans to spin off diabetes business within 18 months
CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.
By Ricky Zipp • May 21, 2025 -
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products
In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.
By Elise Reuter • May 16, 2025 -
Andrew Witty steps down as UnitedHealth CEO
Witty’s departure was surprising, though it follows a sharp downturn in the healthcare juggernaut’s financial outlook. He is being replaced by Stephen Hemsley, the chair of UnitedHealth’s board and a previous chief executive.
By Rebecca Pifer Parduhn • May 13, 2025